Rubbish Check
ABC News Business (AP wire) · September 18, 2026
source“Trump to announce all 50 states joining Medicaid drug pricing model”
R2/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates ABC News' headline that "all 50 states" are joining Trump's Medicaid "GENEROUS" drug pricing model a 2/10 because the claim matches the announced policy fact and the article itself, not the headline, carries the spin risk by pairing an unverifiable savings claim with expert skepticism.
The Verdict
Lightly altered. The headline states exactly what is being announced, all 50 states adopting the most-favored-nation Medicaid model, with no embellishment about dollar savings or outcomes. It earns a couple of points off a clean 1 only because the branded program name ("GENEROUS") and the framing of universal state participation as inherently good news imply a positive spin that the body immediately complicates with unverified-savings caveats.
What actually happened
The Trump administration is set to announce that all 50 states will participate in a Medicaid pricing model, dubbed "GENEROUS," that applies most-favored-nation pricing to some drugs, tying U.S. prices to lower prices paid elsewhere. The administration claims this will save Medicaid billions, but independent verification is not possible because the underlying pharmaceutical deals have not been made public.
Key facts
- All 50 states are joining the Medicaid "GENEROUS" most-favored-nation pricing model, per the administration's Friday announcement.
- The White House separately estimated in May that its broader MFN pharmaceutical deals could save $529 billion over 10 years, a figure that covers deals beyond just Medicaid.
- Medicaid enrollees already pay only a nominal co-payment of a few dollars per prescription, so the savings target is state budgets, not out-of-pocket patient costs.
- Content of the actual pharmaceutical deals is not public, so the projected savings cannot be independently verified.
- Kathy Hempstead of the Robert Wood Johnson Foundation says there is no granular data to justify the cost-savings claims, calling congressional codification premature since "no one knows what is in these deals."
What to watch for
- Whether CMS or the White House releases the actual deal terms with drugmakers, the detail needed to test the "billions saved" claim.
- Whether savings persist past this administration, a concern Hempstead raised directly about deal durability.
- Coverage split on who benefits: Medicaid enrollees pay pennies regardless, so the real audience for this story is state budgets, not patients, a distinction other outlets may blur.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
